MPTP Parkinsonism and Implications for Understanding Parkinson's Disease

被引：10

作者：

AlShimemeri, Sohaila ^{[1
,2
,3
,4
]}

Di Luca, Daniel G. ^{[1
,2
,3
]}

Fox, Susan H. ^{[1
,2
,3
]}

机构：

[1] Toronto Western Hosp, Edmond J Safra Program Parkinson Dis, Toronto, ON, Canada

[2] Univ Hlth Network, Krembil Brain Inst, Toronto, ON, Canada

[3] Univ Toronto, Div Neurol, Toronto, ON, Canada

[4] King Saud Univ, Riyadh, Saudi Arabia

来源：

MOVEMENT DISORDERS CLINICAL PRACTICE | 2022年 / 9卷 / 01期

基金：

美国国家卫生研究院; 加拿大健康研究院;

关键词：

MPTP; model; parkinsonism; NONHUMAN PRIMATE MODELS; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; SUBSTANTIA-NIGRA; NEUROTOXICITY; DOPAMINE; DEPRENYL; NEURONS; MONKEYS; HUMANS; PHASE;

D O I：

10.1002/mdc3.13344

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：42 / 47

页数：6

共 53 条

[1] PARALLEL ORGANIZATION OF FUNCTIONALLY SEGREGATED CIRCUITS LINKING BASAL GANGLIA AND CORTEX [J].

ALEXANDER, GE ;

DELONG, MR ;

STRICK, PL .

ANNUAL REVIEW OF NEUROSCIENCE, 1986, 9 :357-381

[2] PERMANENT HUMAN PARKINSONISM DUE TO 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) - 7 CASES [J].

BALLARD, PA ;

TETRUD, JW ;

LANGSTON, JW .

NEUROLOGY, 1985, 35 (07) :949-956

[3]

BANKIEWICZ KS, 1986, LIFE SCI, V39, P7, DOI 10.1016/0024-3205(86)90431-5

[4] GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop [J].

Barker, Roger A. ;

Bjorklund, Anders ;

Gash, Don M. ;

Whone, Alan ;

Laar, Amber Van ;

Kordower, Jeffrey H. ;

Bankiewicz, Krystof ;

Kieburtz, Karl ;

Saarma, Mart ;

Booms, Sigrid ;

Huttunen, Henri J. ;

Kells, Adrian P. ;

Fiandaca, Massimo S. ;

Stoessl, A. Jon ;

Eidelberg, David ;

Federoff, Howard ;

Voutilainen, Merja H. ;

Dexter, David T. ;

Eberling, Jamie ;

Brundin, Patrik ;

Isaacs, Lyndsey ;

Mursaleen, Leah ;

Bresolin, Eros ;

Carroll, Camille ;

Coles, Alasdair ;

Fiske, Brian ;

Matthews, Helen ;

Lungu, Codrin ;

Wyse, Richard K. ;

Stott, Simon ;

Lang, Anthony E. .

JOURNAL OF PARKINSONS DISEASE, 2020, 10 (03) :875-891

[5] The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results [J].

Beaudry, Francis ;

Huot, Philippe .

JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (10) :1343-1358

[6] Creatine supplementation in Parkinson disease:: A placebo-controlled randomized pilot trial [J].

Bender, A. ;

Koch, W. ;

Elstner, M. ;

Schombacher, Y. ;

Bender, J. ;

Moeschl, M. ;

Gekeler, F. ;

Mueller-Myhsok, B. ;

Gasser, T. ;

Tatsch, K. ;

Klopstock, T. .

NEUROLOGY, 2006, 67 (07) :1262-1264

[7] REVERSAL OF EXPERIMENTAL PARKINSONISM BY LESIONS OF THE SUBTHALAMIC NUCLEUS [J].

BERGMAN, H ;

WICHMANN, T ;

DELONG, MR .

SCIENCE, 1990, 249 (4975) :1436-1438

[8] A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey [J].

Bezard, E ;

Imbert, C ;

Deloire, X ;

Bioulac, B ;

Gross, CE .

BRAIN RESEARCH, 1997, 766 (1-2) :107-112

[9] Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter [J].

Bezard, E ;

Gross, CE ;

Fournier, MC ;

Dovero, S ;

Bloch, B ;

Jaber, M .

EXPERIMENTAL NEUROLOGY, 1999, 155 (02) :268-273

[10] The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future [J].

Bjorklund, Anders ;

Cenci, M. Angela .

RECENT ADVANCES IN PARKINSONS DISEASE: TRANSLATIONAL AND CLINICAL RESEARCH, 2010, 184 :133-157

← 1 2 3 4 5 6 →